Warto dyskutować, warto wiedzieć. Etorykoksyb Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2022
Słowa kluczowe:
etorykoksyb, NLPZ, choroby narządu ruchu
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy omówiono skuteczność i działania niepożądane etorykoksybu. Etorykoksyb jest silnym niesteroidowym lekiem przeciwzapalnym stosowanym w chorobach narządu ruchu. Skuteczność leku jest porównywalna z diklofenakiem. Tolerancja leczenia jest dobra. Etorykoksyb powoduje mniej działań niepożądanych ze strony przewodu pokarmowego i wątroby niż diklofenak, pacjenci rzadziej odstawiają lek. Powikłania sercowo-naczyniowe występują z podobną częstością jak po diklofenaku. Etorykoksyb częściej powoduje wzrost ciśnienia tętniczego.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Rell-Bakalarska, M., & Rell, K. (2022). Warto dyskutować, warto wiedzieć. Etorykoksyb. Medycyna Faktów , 15(4(57), 414-417. https://doi.org/10.24292/01.MF.0422.7
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017; 390: e21-33.
2. Gottesdiener K, Schnitzer T, Fisher C et al. Results of a randomized, dose‐ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology. 2002; 41(9): 1052-61.
3. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
4. Baraf HS, Fuentealba C, Greenwald M et al. Gastrointestinal Side Effects of Etoricoxib in Patients with Osteoarthritis: Results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial. J Reumatol. 2007; 34: 408-20.
5. Krueger K, Lino L, Dore R et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis. 2008; 67(3): 315-22.
6. Matsumoto AK, Melian A, Mandel DR et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002; 29(8): 1623-30.
7. Bickham K, Kivitz AJ, Mehta A. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal antiinflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016; 17: 331.
8. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med. 2020; 19(4): 3031-41.
9. Gratacós J, Moreno M-LM, Font P et al. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol. 2016; 34(1): 94-9.
10. Schumacher Jr HR, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002; 324(7352): 1488-92.
11. Ramey DR, Watson DJ, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5): 715-22.
12. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086.
13. Krum H, Swergold G, Gammaitoni A et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther. 2012; 30(6): 342-50.
14. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69: 365-71.
15. Yaxley J, Litfin T. Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review. Ren Fail. 2016; 38(9): 1328-34.
2. Gottesdiener K, Schnitzer T, Fisher C et al. Results of a randomized, dose‐ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology. 2002; 41(9): 1052-61.
3. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
4. Baraf HS, Fuentealba C, Greenwald M et al. Gastrointestinal Side Effects of Etoricoxib in Patients with Osteoarthritis: Results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) Trial. J Reumatol. 2007; 34: 408-20.
5. Krueger K, Lino L, Dore R et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis. 2008; 67(3): 315-22.
6. Matsumoto AK, Melian A, Mandel DR et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002; 29(8): 1623-30.
7. Bickham K, Kivitz AJ, Mehta A. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal antiinflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016; 17: 331.
8. Fan M, Liu J, Zhao B et al. Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med. 2020; 19(4): 3031-41.
9. Gratacós J, Moreno M-LM, Font P et al. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol. 2016; 34(1): 94-9.
10. Schumacher Jr HR, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002; 324(7352): 1488-92.
11. Ramey DR, Watson DJ, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5): 715-22.
12. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: c7086.
13. Krum H, Swergold G, Gammaitoni A et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther. 2012; 30(6): 342-50.
14. Meek IL, Vonkeman HE, Kasemier J et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013; 69: 365-71.
15. Yaxley J, Litfin T. Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review. Ren Fail. 2016; 38(9): 1328-34.